Atypical Variants of Tardive Dyskinesia, Treated by a Combination of Clozapine with Propranolol and Clozapine with Tetrabenazine

Kalian, Moshe; Lerner, Vladimir; Goldman, Michael

doi:10.1097/00005053-199310000-00014

Cited by 27 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has only a weak D 2 blocking effect and may therefore be less effective in treating tics than other antipsychotics. A few older studies reported successful reductions in tics during monotherapy (as shown by Jaffe et al53 in the context of tardive TS) or in combination with propanolol or tetrabenazine 54. However, clozapine has not been found helpful in the treatment of TS as stated by several case reports which also documented serious adverse events (eg, agranulocytosis) associated with this agent 55.…”

Section: Resultsmentioning

confidence: 99%

Update on the role of antipsychotics in the treatment of Tourette syndrome

Huys¹,

Hardenacke²,

Poppe³

et al. 2012

NDT

View full text Add to dashboard Cite

Tourette syndrome (TS) is a neuropsychiatric disorder with typical onset in childhood and characterized by chronic occurrence of motor and vocal tics. The disorder can lead to serious impairments of both quality of life and psychosocial functioning, particularly for those individuals displaying complex tics. In such patients, drug treatment is recommended. The pathophysiology of TS is thought to involve a dysfunction of basal ganglia-related circuits and hyperactive dopaminergic innervations. Congruently, dopamine receptor antagonism of neuroleptics appears to be the most efficacious approach for pharmacological intervention. To assess the efficacy of the different neuroleptics available, a systematic, keyword-related search in PubMed (National Library of Medicine, Washington, DC) was undertaken. Much information on the use of antipsychotics in the treatment of TS is based on older data. Our objective was to give an update and therefore we focused on papers published in the last decade (between 2001 and 2011). Accordingly, the present review aims to summarize the current and evidence-based knowledge on the risk-benefit ratio of both first and second generation neuroleptics in TS.

show abstract

Section: Resultsmentioning

confidence: 99%

Update on the role of antipsychotics in the treatment of Tourette syndrome

Huys¹,

Hardenacke²,

Poppe³

et al. 2012

NDT

View full text Add to dashboard Cite

show abstract

“…A search in the literature has shown that there are some solitary reports about its use in combination with pimozide [23] for the treatment of spontaneous oral dyskinesias, and with CLOZ [16] for the management of psychosis with hyperkinesias.…”

Section: Discussionmentioning

confidence: 99%

“…In the past, several reports have shown the beneficial effect of CLOZ, alone or combined with other medications, on TD [13][14][15][16]. Moreover, it has been considered to be the drug of choice for patients with TD [17], although one group did not confirm this data [18].…”

Section: Introductionmentioning

confidence: 99%

Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study

et al. 2011

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a complex involuntary movement disorder affecting about 23% of neuroleptic-treated patients. Our objective was to retrospectively analyze a combination of tetrabenazine (TBZ), clonazepam (CLONAZ) and clozapine (CLOZ) used simultaneously for TD in psychotic patients. Six patients with severe, unsuccessfully controlled TD were referred for treatment (mean age 51.5 years; three male; four schizophrenics; one bipolar disease; one borderline personality disorder). They were being treated with neuroleptics (classic, three; risperidone, two; olanzapine, one) and developed severe neck and buccolingual dyskinesias. At our clinic, all of them were treated simultaneously with TBZ (mean dose 141.6 mg); CLONAZ (mean dose 4.3 mg); and CLOZ (mean dose 125 mg). In parallel, we stopped the offending medication. With 1 week, we observed a very impressive improvement in symptoms and within 1 month all the patients were free of symptoms. The mean observation period was 4 years. The combination of TBZ, CLONAZ and CLOZ is a rapid and beneficial option for the management of TD. An augmentation effect probably played a role in the rapid alleviation of symptomatology.

show abstract

“…The responsiveness of tics to treatment with clozapine has been inconsistent; insignificant in one clinical study of 12 patients [41], but effective in some case reports [42]. This medication has been used successfully in combination with either propranolol or tetrabenazine to treat tardive TS [43,44]. The clinically significant side effects of agranulocytosis and seizures severely restrict the use of this medication.…”

Section: Othersmentioning

confidence: 99%

The treatment of tics

Singer

2001

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Tics are the essential component of a variety of disorders, notably Tourette syndrome. Because the mere presence of tics does not require therapeutic intervention, criteria are essential for determining a functional disability. Suggested tic-suppressing treatments have been extremely diverse, including hydrotherapy, behavioral treatments, pharmacotherapy, botulinum toxin, immunomodulatory therapy, and surgery. This manuscript reviews each of these approaches with emphasis on more recent pharmacologic trials.

show abstract

Atypical Variants of Tardive Dyskinesia, Treated by a Combination of Clozapine with Propranolol and Clozapine with Tetrabenazine

Cited by 27 publications

References 0 publications

Update on the role of antipsychotics in the treatment of Tourette syndrome

Update on the role of antipsychotics in the treatment of Tourette syndrome

Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study

The treatment of tics

Contact Info

Product

Resources

About